Background: Leukaemia is the eleventh commonest UK cancer. The four main sub-types have
INTRODUCTION
Leukaemia is characterised by proliferation of abnormal leukocytes. 1 There are four main subtypes:
chronic myeloid leukaemia (CML), chronic lymphocytic leukaemia (CLL), acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL). The incidence, clinical presentation and survival all vary by subtype. Around 8,600 UK people are diagnosed with leukaemia with 4,800 deaths annually.
It mainly a disease of adults, with 88% of new diagnoses occurring in the over 40s. [1] [2] [3] [4] [5] The latest leukaemia survival figures show a reduction in the percentage of 'avoidable UK deaths' from 4.5% (1985-89) to 1.3% (1995-99); however, a discrepancy in mortality between the rich and poor in England still exists. 6 7 Updated UK guidance on the diagnosis of leukaemia gives several symptoms which GPs may consider investigating by a full blood count; however, none of these recommendations was based on primary care evidence. 8 Diagnosis generally follows symptomatic presentation to a health professional, usually in primary care, prompting blood testing or through an incidental blood test result when leukaemia had not been considered. No primary care symptomatic papers have been published. One secondary care
paper reported the percentage of patients with symptomatic presentations: these were least frequent in CLL (47%) compared with 71% in CML, 77% in AML and 78% in ALL. Tiredness and pain were common to all leukaemias but some symptoms were more specific: chest pain in AL;
bruising/bleeding and shortness of breath/cough in AML, masses in ALL and CLL and abnormal sweating in CL. 9 Another study of over 5,000 CLL patients reported infection in32%, fatigue in 17%
and lymphadenopathy in 7%, with splenomegaly and excessive sweating much rarer. 10 For CML, fatigue has been reported in nearly 34%, with bleeding and weight loss in 21% and 20% respectively. 11 Infection, headache, cough, malaise and nausea were rarer, reported in 7% of cases. For the acute leukaemias, fatigue, haemorrhage, fever and infection are common in AML, whilst fatigue, infection, bone pain, fever, bruising/bleeding and petechiae have been reported in ALL. 12 13 Haematological abnormalities in CLL have been reported up to ten years before diagnosis, with monoclonal B-cell lymphocytosis (MBL) believed to be a precursor condition in almost all CLL patients 14 .
Declining haemoglobin values have been reported in lymphatic leukaemias beginning five years before diagnosis. 15 This study aimed to identify and quantify the separate primary care symptom-only profiles of chronic and acute leukaemias, to guide GPs when to initiate blood tests for possible leukaemia. We also took the opportunity to assess how the lymphocyte count changes in the five years before a diagnosis of CLL.
METHODS
This was a matched case-control study using electronic patient record data from the UK's Clinical Practice Research Datalink (CPRD). The methods follow those of our other primary care cancer papers. 16 17 The CPRD contains anonymised primary care medical records from around 680 UK general practices, representing 8.8% of the population. Personal information is collected, as well as clinical events such as symptom reporting, diagnoses, prescriptions and investigation results. Blood test results were not included in the primary analysis as most patients having blood tests will have a full blood count, which in almost always reveal any leukaemia. Secondary analyses included adding the white cell count to the final multivariable model, and examined pre-diagnostic lymphocyte counts over five years. Recording bias was tested using a feature thought to have no association with leukaemia -fracture.
Cases and controls

Analysis and statistical methods
The main analytical method was conditional logistic regression. Variables with a p-value of ≤0.1 from univariable analysis entered multivariable analysis. Features were grouped according to similaritysuch as abdominal pain, back pain, chest pain. All features from the group stage attaining a p-value threshold of ≤0.05 entered final modelling, which used a p≤0.01 threshold for retention. Clinically plausible interaction terms and lymphoid/myeloid interactions were tested against the final model and retained if their p-value was ≤0.01.
Positive predictive values (PPVs) for the risk of CL or AL was calculated separately using Bayes' theorem (prior odds x likelihood ratio = posterior odds). Prior odds were calculated from the agespecific national incidence of CL and AL for 2008, expressed as odds. PPVs were estimated for consulting patients only: thus, the posterior odds for CL were divided by 0.910 as 1,272 (9%) of 14,103 eligible controls were non-consulters. The conversion factor for AL was 0.915 respectively. A separate analysis of the lymphocyte count (selected in preference to the WCC, as it is more specific for CLL) was conducted in CLL, and values in the five years before diagnosis plotted as a monthly moving average.
Power calculation
Initial estimates from the CPRD indicated approximately 3,000 CL and 1,000 AL cases were available; these transpired to be minor overestimates. A power calculation showed that for CL, there was >98% power to detect a difference in a rare variable present in 2% cases and 1% of controls. For a commoner variable, there was >99% power to detect a difference in prevalence of 20% in cases to 15% in controls. For AL, power was >98% for detecting a difference from3% in cases to 1% in controls and >96% power 20% in cases and 15% in controls. All analysis was conducted using Stata software, version 13.1.
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RESULTS
The CPRD supplied 27,619 patients (4,673 cases and 22,946 controls). After applying the exclusion criteria ( Figure 1 Patient demographic and consultation information is given in Table 1 . CL and AL cases consulted significantly more frequently than controls in the year before diagnosis (p=<0.001; ranksum test). Table 2 here
Positive predictive values
PPVs were calculated for the over 60s, targeting patients around the average age of leukaemia diagnosis -accounting for 83% of CL cases, and 82% of AL cases. For CL, the highest PPV was 0.34% for lymphadenopathy; weight loss, bruising and fatigue were all under 0.01%. Lymphadenopathy with cough had the highest combined PPV of 0.27%; many combinations were too rare to allow a PPV calculation. For AL, all single symptoms had PPVs < 0.01%. Fever with infection produced the highest combined PPV of 0.13%.
Lymphocyte counts in the years before diagnosis of CLL
The lymphocyte counts in 1,751 out of 2379 (74%) CLL cases in the five years before the index date are shown in figure 2 . The graph indicates a steady increase in lymphocyte count in cases, becoming greater in the 6 months before a CLL diagnosis. Many abnormally high values were present up to five years before diagnosis. 
Strengths and limitations
The use of the CPRD ensured good data quality, a large sample size, and a representative spread of patients across the UK. Analysis by sub-type, gender and age was possible, allowing the identification of relevant symptoms, though even this large dataset was insufficient for some symptom combinations, which were simply too rare in controls. The selection of putative symptoms was inclusive and derived from our literature review, supplemented by self-reported symptoms. It is unlikely that pertinent symptoms were excluded.
Nearly a fifth of the total leukaemia cases had a generic leukaemia code which could not be categorised to either AL or CL: we omitted them from study. This is unlikely to have introduced bias, though it will have reduced power a little.
Recording of duration and severity of symptoms is generally poor in GP notes, and GPs appear to preferentially record diagnoses over symptoms. Information on cancer staging is also poor, preventing sub-analyses of, for example, early stage cancers. GPs can choose to record information in a free text ('uncoded') section which is generally not available to researchers: this can influence the results if such differential recording occurs preferentially in either cases or controls -though this affect appears to be minor. 19 Cases have a higher attendance rate, thereby increasing the chance of reporting a symptom. However, our test for this bias, of the fracture rate, did not support this potential concern.
Comparison with existing literature
Tiredness has been reported in the secondary care literature: both malaise and fatigue were present, but with a higher prevalence in AL. [9] [10] [11] Similarly, we only found chest pain to be associated with AL. 9 Bruising, previously reported in AML patients, was found in both CL and AL but twice as commonly in AL. Shortness of breath, also previously reported in AML patients, was significant in both CL and AL; cough was only found in CL, as has been reported for CML previously. 11 The symptom with the highest odds ratio, lymphadenopathy, which was previously reported in ALL and CLL, was only found in CLL patients in this study. 9 Hypertension was significantly associated with CL, but with such a small odds ratio as to be of little value clinically. Finally, raised lymphocytes long before a CLL diagnosis has been reported in the secondary care literature before.
Implications for practice
In theory, primary care diagnosis of leukaemia should be easy, as nearly all leukaemias have abnormal full blood counts. Indeed, many leukaemias -especially CLL, are identified serendipitously, with possible leukaemia not considered likely -or at all -at the time of testing. 9 Ideally we would have separated the truly asymptomatic group of patients from those with a symptom which did not reach the final model; however this was not possible, as our methods only included putative leukaemia symptoms, and omitted symptoms deemed irrelevant. It is likely most patients having a full blood count were symptomatic, even if the symptoms were not those of leukaemia. Only 51% of our CL patients had a symptom appearing in the final model; this suggests roughly half are serendipitously discovered. Thus our results should be seen as symptoms which should prompt consideration of a blood count. The symptoms largely match those in the revised NICE guidancewhich combined all forms of leukaemia. However, shortness of breath, chest and abdominal pain and diarrhoea are not included in the guidance.
It was not clear what events had triggered full blood counts in our cases, particularly those who were apparently asymptomatic. Blood testing is remarkably common in primary care, with approximately a quarter of those over thirty having a full blood count in any one year. 20 The clinical problem is that all PPVs are tiny. All the symptoms reported here have much more likely benign alternative explanations, though some of the alternative diagnoses -such as anaemiawould require a blood count to be taken for diagnosis. In truth, however, the small possibility of leukaemia will only add marginally to the decision to investigate by a blood count. Some symptoms, such as fatigue, are frequently investigated, particularly when persistent. 21 A second group of symptoms often suggests important underlying disease, such as weight loss, bruising, nose bleeds bleeding gums or lymphadenopathy, especially in the over 60s: our results suggest that a blood count should be included in investigation of these. The graph of lymphocyte counts before diagnosis of CLL suggests there is a considerable opportunity to expedite the diagnosis; this could include software in the primary care clinical systems or in the reporting laboratory which could alert the GP to a raised white cell count, mentioning the possibility of CLL. This is supported by the analysis retaining WCCs in the chronic leukaemia model, showing a very high odds-ratio with only lymphadenopathy adding much to the predictive power of the model. Indeed, it is plausible other haematological measures are changing in the years before CLL is diagnosed: this is an avenue for further study. Although treatment of early CLL is sometimes considered, many patients are observed without active treatment initially, so the imperative to diagnose early is arguably much less in CLL than in most other cancers.
Conclusion
Leukaemia is relatively rare. We have identified a number of symptoms related to either chronic or acute leukaemia -or both. No symptom stands out as a high risk marker of the disease, though many of the symptoms would lead to testing which would then reveal the underlying leukaemia.
This probably explains why most diagnoses are serendipitous -and are likely to remain so, especially as the number of patients having blood counts increases.
Total number n=27,619
Total number n=27,619 
